Wall St analysts Dresdner Kleinwort said "We expect Ambien's share to be decimated within a month,but Ambien CR (controlled-release) held 31% of the Ambien franchise TRX and 18% of the insomnia TRX, mitigating the effect on Sanofi."
« Exclusive! David Beckham NOT in Deal With Botox | Main | Hello, AZ Group of 7. Lawyers Would Like to Talk to You! »
May 18, 2007
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d834519bc269e200d83579e49469e2
Listed below are links to weblogs that reference Ambien vs. Generic Competition: Not as Bad as It Could Have Been:
The comments to this entry are closed.
Author
Peter Rost, M.D. writes for BrandweekNRX since August 1, 2007. Dr. Rost is a former VP of Pfizer engaged as a pharma expert witness and pharmaceutical marketing consultant by several law firms. He also writes the daily Pharma Law Blog and is the author of Killer Drug and The Whistleblower. Contact Dr. Rost by clicking here.
Search
February 2008
Categories
Recent Posts
- Hello. Goodbye.
- Pfizer's disgraced Dr. Jarvik talks to Playboy about manufacturing a dildo and his sex life.
- Sex, drugs, doctors, and . . . pharma sales reps.
- Dr. Jarvik: I can row! I can row!
- Pfizer dumps Jarvik after numerous lies exposed.
- EdrugSearch.com Community
- 44% of all cigarettes smoked by people with mental illness.
- Picture of a future president?
- Restrooms and advertising. We love both.
- Nader will run again - and proposes real universal healthcare.
Comments